IN2012DN02103A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02103A IN2012DN02103A IN2103DEN2012A IN2012DN02103A IN 2012DN02103 A IN2012DN02103 A IN 2012DN02103A IN 2103DEN2012 A IN2103DEN2012 A IN 2103DEN2012A IN 2012DN02103 A IN2012DN02103 A IN 2012DN02103A
- Authority
- IN
- India
- Prior art keywords
- compounds
- maintenance
- treatment
- conditions
- induction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24432709P | 2009-09-21 | 2009-09-21 | |
PCT/US2010/049714 WO2011035330A2 (en) | 2009-09-21 | 2010-09-21 | Oxytocin receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02103A true IN2012DN02103A (zh) | 2015-08-21 |
Family
ID=43629442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2103DEN2012 IN2012DN02103A (zh) | 2009-09-21 | 2010-09-21 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8748564B2 (zh) |
EP (1) | EP2491052A2 (zh) |
JP (1) | JP5750443B2 (zh) |
KR (1) | KR20120093840A (zh) |
CN (1) | CN102656183B (zh) |
AR (1) | AR078304A1 (zh) |
AU (1) | AU2010295294B2 (zh) |
BR (1) | BR112012006185A2 (zh) |
CA (1) | CA2774593C (zh) |
IL (1) | IL218649A (zh) |
IN (1) | IN2012DN02103A (zh) |
MX (1) | MX2012003208A (zh) |
NZ (1) | NZ598579A (zh) |
RU (1) | RU2539692C2 (zh) |
SA (1) | SA110310710B1 (zh) |
TW (1) | TWI463990B (zh) |
WO (1) | WO2011035330A2 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
KR101819804B1 (ko) | 2012-12-21 | 2018-01-17 | 에프. 호프만-라 로슈 아게 | 옥시토신 작용제로서의 펩타이드 |
PE20161559A1 (es) * | 2014-06-03 | 2017-01-12 | Hoffmann La Roche | Peptidos como agonistas de la oxitocina |
CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
WO2016025629A1 (en) | 2014-08-12 | 2016-02-18 | The Regents Of The University Of California | Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues |
US10441627B2 (en) * | 2014-09-19 | 2019-10-15 | Ferring B.V. | Method of treating prader-willi syndrome |
AU2015338717B2 (en) | 2014-10-31 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
CN108290929A (zh) * | 2015-10-06 | 2018-07-17 | 辉凌公司 | 制造巴芦西班及其中间体的新型方法 |
CN106967155B (zh) * | 2017-03-17 | 2018-05-15 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
WO2019032946A1 (en) | 2017-08-11 | 2019-02-14 | Ferring B.V. | PROCESS FOR PRODUCING OXYTOCIN |
WO2019060962A1 (en) * | 2017-09-28 | 2019-04-04 | The University Of Sydney | SELECTIVE AGONISTS OF THE OCYTOCIN RECEPTOR, INSPIRED BY METABOLITES |
EP3768320A1 (en) | 2018-03-23 | 2021-01-27 | Cytoo | Alk5 inhibitors as skeletal muscle hypertrophy inducers |
WO2020061414A1 (en) | 2018-09-20 | 2020-03-26 | Levo Therapeutics, Inc. | Stable intranasal formulations of carbetocin |
TW202034899A (zh) | 2018-09-20 | 2020-10-01 | 克里斯托弗 S 布萊恩特 | 卡貝縮宮素藥品及其製備方法 |
KR20220097360A (ko) | 2019-11-04 | 2022-07-07 | 훼링 비.브이. | 수유 개선을 위한 메로토신의 비강내 투여 |
KR20240007126A (ko) | 2021-03-26 | 2024-01-16 | 오티4비 | 연하곤란의 치료 |
WO2023118303A1 (en) | 2021-12-21 | 2023-06-29 | Universitaet Wien | Highly stable oxytocin derivatives |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS194980B1 (en) * | 1976-07-16 | 1979-12-31 | Joseph H Cort | Agent for current induction,fertilization facilitating and milkability increasing at mammals,especially at utility cattle |
SE430885B (sv) * | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
CS216722B1 (en) * | 1980-06-24 | 1982-11-26 | Michal Lebl | Oxytocine analogues and method of making the same |
US4483794A (en) * | 1983-05-10 | 1984-11-20 | Ceskoslovenska Akademie Ved | Analogs of neurohypophysial hormones |
SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
WO2002058721A1 (en) * | 2000-12-08 | 2002-08-01 | Baylor College Of Medicine | Trem-1 splice variant for use in modifying immune responses |
JP4615221B2 (ja) | 2002-02-27 | 2011-01-19 | フェリング ベスローテン フェンノートシャップ | ヘプタペプチドオキシトシンアナログを製造するための中間体及び方法 |
CA2641959C (en) * | 2006-02-10 | 2016-12-20 | Ferring B.V. | Novel compounds |
-
2010
- 2010-09-08 TW TW099130296A patent/TWI463990B/zh not_active IP Right Cessation
- 2010-09-20 SA SA110310710A patent/SA110310710B1/ar unknown
- 2010-09-21 NZ NZ598579A patent/NZ598579A/en not_active IP Right Cessation
- 2010-09-21 EP EP10777131A patent/EP2491052A2/en not_active Withdrawn
- 2010-09-21 BR BR112012006185A patent/BR112012006185A2/pt not_active IP Right Cessation
- 2010-09-21 CA CA2774593A patent/CA2774593C/en not_active Expired - Fee Related
- 2010-09-21 AU AU2010295294A patent/AU2010295294B2/en not_active Ceased
- 2010-09-21 AR ARP100103440A patent/AR078304A1/es unknown
- 2010-09-21 IN IN2103DEN2012 patent/IN2012DN02103A/en unknown
- 2010-09-21 WO PCT/US2010/049714 patent/WO2011035330A2/en active Application Filing
- 2010-09-21 RU RU2012110349/04A patent/RU2539692C2/ru not_active IP Right Cessation
- 2010-09-21 MX MX2012003208A patent/MX2012003208A/es active IP Right Grant
- 2010-09-21 JP JP2012529981A patent/JP5750443B2/ja not_active Expired - Fee Related
- 2010-09-21 CN CN201080041788.0A patent/CN102656183B/zh not_active Expired - Fee Related
- 2010-09-21 US US13/496,269 patent/US8748564B2/en not_active Expired - Fee Related
- 2010-09-21 KR KR1020127006787A patent/KR20120093840A/ko not_active Application Discontinuation
-
2012
- 2012-03-15 IL IL218649A patent/IL218649A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2011035330A2 (en) | 2011-03-24 |
IL218649A (en) | 2016-11-30 |
MX2012003208A (es) | 2012-05-29 |
EP2491052A2 (en) | 2012-08-29 |
CA2774593A1 (en) | 2011-03-24 |
AU2010295294A1 (en) | 2012-03-29 |
SA110310710B1 (ar) | 2015-01-05 |
RU2012110349A (ru) | 2013-10-27 |
CA2774593C (en) | 2016-12-06 |
TW201114434A (en) | 2011-05-01 |
WO2011035330A3 (en) | 2011-05-19 |
IL218649A0 (en) | 2012-05-31 |
JP5750443B2 (ja) | 2015-07-22 |
JP2013505269A (ja) | 2013-02-14 |
CN102656183A (zh) | 2012-09-05 |
BR112012006185A2 (pt) | 2016-05-31 |
RU2539692C2 (ru) | 2015-01-27 |
AU2010295294B2 (en) | 2015-12-10 |
NZ598579A (en) | 2014-02-28 |
AU2010295294A8 (en) | 2012-05-31 |
WO2011035330A4 (en) | 2011-07-07 |
US20120214733A1 (en) | 2012-08-23 |
KR20120093840A (ko) | 2012-08-23 |
US8748564B2 (en) | 2014-06-10 |
CN102656183B (zh) | 2016-03-30 |
TWI463990B (zh) | 2014-12-11 |
AR078304A1 (es) | 2011-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02103A (zh) | ||
PH12015501289B1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
MY153976A (en) | Lh liquid formulations | |
MX342161B (es) | Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3. | |
UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
MY175854A (en) | Novel quinolone derivatives | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
TN2012000534A1 (en) | Pyrazole compounds as sigma receptor inhibitors | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
MX2014000142A (es) | Uso de anticuerpos agonistas anti-cd83 para tratar enfermedades autoinmunes. | |
IN2014MN00697A (zh) | ||
IN2014CN02364A (zh) | ||
GEP20156231B (en) | Agomelatine hydrochloride hydrate and preparation there of | |
MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. | |
MX2014002394A (es) | Inhibidores de rock suaves, novedosos. | |
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
IN2013DN02555A (zh) | ||
IN2014KN00849A (zh) | ||
GEP20156232B (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
IN2014KN00847A (zh) | ||
MX2015006871A (es) | Proceso de cristalizacion de derivados de indoles triciclicos. |